Therapy

• FDA has approved an investigational new drug application for synthetic CAR-T (sCAR-T) therapy targeting autoimmune conditions. • The clearance enables clinical trials to test this engineered cell therapy in US patients with refractory autoimmune diseases. • sCAR-T represents a novel approach adapting cancer immunotherapy for immune disorders, potentially offering durable remissions.

Treatment reset wayward immune system of patient with life-threatening conditions, say scientists, in a world firstA woman who lived with three life-threatening autoimmune diseases for more than a decade has returned to a near-normal life after a cell therapy reset her wayward immune system.The 47-year-old had had nine different treatments, none of which had a lasting impact, before receiving the therapy last year at University Hospital Erlangen in Germany. At the time, she required daily blood transfusions and permanent blood thinning medication to control her illness. Continue reading...

• NIH awarded $500 million in grants on April 7, 2026, to 15 US institutions for CRISPR-based gene therapies addressing 100,000 Americans with sickle cell disease. • Phase 2 trials at Boston Children's show 94% pain crisis reduction; total funding supports 200 patients over five years. • Initiative responds to 17% US mortality drop goal by 2030; 'Breakthrough for underserved communities,' per NIH Director.

• Combination therapy of ixekizumab and tirzepatide yields better results in psoriatic arthritis patients compared to ixekizumab alone, per recent medical research. • This finding advances treatment options for the chronic inflammatory condition affecting joints and skin. • Updated clinical approaches could enhance patient quality of life and disease management.

• A Philadelphia cancer patient who had exhausted conventional treatment options was kept alive using a novel T-cell therapy developed and administered at Rutgers Health. • The case represents a breakthrough application of immunotherapy, offering hope to patients facing terminal cancer diagnoses with limited options. • The success demonstrates the therapeutic potential of advanced cellular therapies and highlights Rutgers Health's role in pioneering cutting-edge cancer treatment innovations.

• The MajesTEC-3 clinical trial led by UAB researchers demonstrates that a new two-drug immunotherapy regimen can lead to long-lasting remission for multiple myeloma patients. • Over 83 percent of patients enrolled in the trial remain alive and progression-free three years after therapy, supporting approval of this potentially curative treatment. • The findings represent a significant advance for multiple myeloma, a blood cancer with limited treatment options historically.

• The U.S. Supreme Court ruled 6-3 on April 1, 2026, that state bans on conversion therapy for minors violate counselors' First Amendment rights. • The decision overturns California's pioneering 2012 law and similar measures in over 20 states prohibiting practices aimed at changing sexual orientation. • Chief Justice Roberts wrote the majority opinion, emphasizing licensed professionals' speech protections in private counseling.